A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Public ClinicalTrials.gov record NCT04544436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIb Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS, in comparison to the approved 600 milligrams (mg) dose of ocrelizumab.
Study identification
- NCT ID
- NCT04544436
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 864 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2020 (Actual)
- Primary completion
- Dec 19, 2024 (Actual)
- Completion
- Feb 21, 2028 (Estimated)
- Last update posted
- Sep 28, 2026
2020 – 2028
United States locations
- U.S. sites
- 25
- U.S. states
- 20
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| North Central Neurology Associates | Cullman | Alabama | 35058 | — |
| Alabama Neurology Associates | Homewood | Alabama | 35209 | — |
| 21st Century Neurology | Phoenix | Arizona | 85004 | — |
| Profound Research, LLC | Carlsbad | California | 92011 | — |
| Stanford University Medical Center | Stanford | California | 94305 | — |
| Advanced Neurology of Colorado, LLC | Fort Collins | Colorado | 80528 | — |
| Neurology Associates, PA | Maitland | Florida | 32751 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| American Health Network Institute, LLC | Avon | Indiana | 46123 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| The NeuroMedical Clinic of Central Louisiana | Alexandria | Louisiana | 71301 | — |
| Maine Medical Center | Scarborough | Maine | 04074 | — |
| Dragonfly Research, LLC | Wellesley | Massachusetts | 02481 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Cleveland Clinic Lou Ruvo | Las Vegas | Nevada | 89106 | — |
| Dent Neurological Institute | Amherst | New York | 14226 | — |
| UC Health Neurology | Dayton | Ohio | 45417 | — |
| Oklahoma Medical Research Foundation | Oklahoma City | Oklahoma | 73104 | — |
| Abington Neurological Associates | Willow Grove | Pennsylvania | 19090 | — |
| Tri-State Mountain Neurology | Johnson City | Tennessee | 37604 | — |
| Hope Neurology | Knoxville | Tennessee | 37922 | — |
| Bhupesh Dihenia M.D. P.A. | Lubbock | Texas | 79410 | — |
| Lone Star Neurology of San Antonio | San Antonio | Texas | 78258 | — |
| Evergreen MS Center | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04544436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04544436 live on ClinicalTrials.gov.